VCEL

Vericel

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

consensus rating "Strong Buy"

Revenue Beats Expectation

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About VCEL

Vericel Corporation

A leader in advanced therapies for the sports medicine and severe burn care markets

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

02/04/1997

Exchange

NASDAQ Stock Exchange

Full-time Employees

357

Fiscal Year Ends

12-31

Website

www.vcel.com

Security Type

Common stock

Office address

64 Sidney Street, Cambridge, MA 02139

Business

Introduction

Founded in 1989, Vericel Corporation is a regenerative medicine company focused on the development of innovative cell therapies to repair or regenerate damaged or diseased tissue. The company is developing multicellular therapies for specific patients with severe, chronic ischemic cardiovascular and cerebrovascular diseases. The company believes that ixmyelocel-T is a multifunctional disease improvement therapy that includes tissue remodeling, immune regulation and promotion of angiogenesis. The company's proprietary battery manufacturing technology makes it possible to manufacture multicellular therapies that expand the bone marrow of adult patients and deliver them directly to damaged tissue. Preclinical and clinical data suggest that ixmyelocel-T may be safe and effective in the treatment of severe, chronic ischemic cardiovascular diseases such as severe limb ischemia (CLI), the most serious peripheral artery disease (PAD), and dilated cardiomyopathy (DCM), the third leading cause of heart failure.

Company Financials

EPS

VCEL has released its 2024 Q4 earnings. EPS was reported at 0.38, versus the expected 0.34, beating expectations. The chart below visualizes how VCEL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VCEL has released its 2024 Q4 earnings report, with revenue of 75.38M, reflecting a YoY change of 15.97%, and net profit of 19.81M, showing a YoY change of 52.44%. The Sankey diagram below clearly presents VCEL’s revenue sources and cost distribution.